Maplebear (NASDAQ:CART – Free Report) had its target price hoisted by JPMorgan Chase & Co. from $55.00 to $62.00 in a research note published on Friday morning,Benzinga reports. They currently have an overweight rating on the stock. CART has been the topic of a number of other reports. Oppenheimer raised their price objective on shares […]
| # | Наименование новости | Тональность | Информативность | Дата публикации |
|---|---|---|---|---|
| 1 | TG Therapeutics (NASDAQ:TGTX) Price Target Raised to $72.00 | 0 | 13.04 | 10-08-2026 |
| 2 | Cadre (NYSE:CDRE) Price Target Raised to $45.00 | 0 | 13.85 | 10-08-2026 |
| 3 | Royalty Pharma (NASDAQ:RPRX) Price Target Raised to $62.00 | 0 | 13.82 | 10-08-2026 |
| 4 | Target (NYSE:TGT) Price Target Raised to $157.00 | 0 | 13.85 | 10-08-2026 |
| 5 | Cabot (NYSE:CBT) Price Target Raised to $78.00 | 0 | 14.69 | 10-08-2026 |
| 6 | CACI International (NYSE:CACI) Price Target Raised to $715.00 | 0 | 14.65 | 10-08-2026 |
| 7 | Qiagen (NYSE:QGEN) Price Target Raised to $50.00 | 0 | 14.26 | 10-08-2026 |
| 8 | Once Upon A Farm (NYSE:OFRM) Price Target Raised to $26.00 | 0 | 12.63 | 10-08-2026 |
| 9 | Replimune Group (NASDAQ:REPL) Price Target Raised to $20.00 | 0 | 13.83 | 10-08-2026 |
| 10 | Genpact (NYSE:G) Price Target Raised to $45.00 | 0 | 14.26 | 10-08-2026 |